Search
Major Depressive Disorder Clinical Trials
A listing of 127 Major Depressive Disorder clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
37 - 48 of 127
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Major Depressive Disorder
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 127 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode forat least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode forat least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
Recruiting
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).
The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/24/2025
Locations: Yuma CNS Research, Yuma, Arizona +61 locations
Conditions: Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/20/2025
Locations: IMA Clinical Research Phoenix, Phoenix, Arizona +18 locations
Conditions: Major Depressive Disorder
Near Infrared Spectroscopy (NIRS) for Assessment of Depression
Recruiting
Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control, non-depressed subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: San Francisco Veterans Affairs Medical Center, San Francisco, California
Conditions: Major Depressive Disorder
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are:
Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)?
What medical problems are observed in participants who take GATE-251?
Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/18/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +28 locations
Conditions: Major Depressive Disorder
Biomarker-guided rTMS for Treatment Resistant Depression
Recruiting
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magnetic resonance imaging (fMRI) to confirm a way to optimize the use of rTMS to treat depression. In addition, the study aims to gain a better understanding of how rTMS influences brain networks.
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
03/17/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Treatment Resistant Depression, Major Depressive Disorder
Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
Recruiting
Anhedonia, the inability to seek-out and experience pleasure, is a common symptom in depression that predicts treatment-resistance and is sometimes exacerbated by first-line antidepressants. In our previous research, we found that anhedonia decreases goal-directed behavior and its related neural activity. In this study, we will investigate target engagement from five-consecutive days of stimulation for participants that are within a unipolar major depressive episode and also have high symptoms o... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: Florida State University, Tallahassee, Florida
Conditions: Major Depressive Disorder, Anhedonia
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
Recruiting
The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: Harvard Medical School, Boston, Massachusetts +2 locations
Conditions: Major Depressive Disorder
Imaging Depression in Parkinson's Disease
Recruiting
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/04/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Parkinson's Disease, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
Recruiting
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/04/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Borderline Personality Disorder, Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Recruiting
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Neurocrine Clinical Site, Orange, California +5 locations
Conditions: Major Depressive Disorder
ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
Recruiting
This study aims to determine whether treatment of CMV positive (CMV+) individuals with major depressive disorder (MDD) with valganciclovir (VGCV) alters neural circuitry, reduces inflammation, and improves depressive behavior and symptoms to a greater extent than placebo. In this double-blind, randomized placebo-controlled, parallel group trial, 24 individuals with a Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scale score ≥ 14 will be enrolled to participate in an 8-week t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Major Depressive Disorder
Neural Response to Inflammatory Challenge in Major Depressive Disorder
Recruiting
This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus. This will yield the following groups: MDD-LPS (n=60), MDD-Placebo (n=30), HC-LPS (n=60), HC-placebo (n=30).
There are three main aims: to identify immune pathways and neural circuits that respond differently t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Major Depressive Disorder
37 - 48 of 127